BlueWind Medical Receives FDA Approval for Pivotal Trial Design of RENOVA iStim™ Implantable Tibial Nerve Neuromodulator for Overactive Bladder

The OASIS pivotal trial (OverActive bladder StImulation System study) is designed to evaluate the safety and effectiveness of BlueWind’s RENOVA iStim™ Tibial Stimulation System for the treatment of urinary urgency incontinence in patients who have failed or could not tolerate more conservative treatments.

Pythagoras Medical Receives CE-Mark for the ConfidenHT™ System

Unique nerve mapping technology for renal denervation (RDN) procedure provides more effective treatment for resistant hypertension

Enopace Biomedical Voted #1 Medical Innovation Company

Enopace Selected as 2017’s Top Medical Innovation Company by World Leading Cardiologists and Industry Professionals at TCT in Colorado

Vascular Dynamics Interim Data on MobiusHD Presented at TCT Conference Shows
Significant Reductions in Ambulatory Systolic Blood Pressure At Six Months

Vascular Dynamics, Inc., will present updated interim results of the company’s first-in-human trial of its MobiusHD® implant today at the TCT conference in Denver. The data showed an average reduction of ambulatory systolic blood pressure of more than 19 mmHg from baseline at the 6-month endpoint in studies conducted in the US and EU.

Vascular Dynamics Announces FDA Approval to Initiate
CALM 2 Trial for MobiusHD^® System

Vascular Dynamics, Inc., a privately held medical device company developing novel solutions for the treatment of hypertension, today announces that the United States Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) application to initiate its pivotal trial for its MobiusHD^® System for the treatment of resistant hypertension.

Vascular Dynamics is Featured on ISRAEL21c

Vascular Dynamics, and its MobiusHD device for treatment of resistant hypertension, are featured on the ISRAEL21c online magazine. The article describes the company, technology and clinical trials results which to date have shown that upon discharge, MobiusHD patients’ clinical blood pressure is down about 36 points.

GluSense Receives Investment from JDRF T1D Fund

GluSense Ltd., a medical device company developing a long lasting injectable glucose sensor for treatment of Type 1 Diabetes (T1D), today announced it has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial programs.

Vascular Dynamics’ Announces Expedited Access Pathway Designation by FDA for MobiusHD® to Accelerate US Access for Treatment of Resistant Hypertension

­Vascular Dynamics, Inc., is a privately held medical device company developing novel solutions for the treatment of hypertension, today announces that the United States Food and Drug Administration (FDA) has approved the company’s application to participate in the Expedited Access Pathway (EAP) program for its MobiusHD ® device for the treatment of resistant hypertension.

BlueWind Medical Announces CE-Mark for the BlueWind VIVENDI™ miniature implanted wireless stimulator to treat Peripheral Pain

Bluewind Medical, developer of a miniature wireless neurostimulation platform to treat multiple clinical indications, announced today that the company has received CE-Mark for the BlueWind’s VIVENDI miniature wireless neurostimulator to treat Peripheral Neuropathic Pain (PNP).

BlueWind Medical Announces CE-Mark for BlueWind RENOVA™, the first in the world miniature wireless neurostimulator to treat Overactive Bladder

Bluewind Medical, developer of a miniature wireless neurostimulation platform to treat multiple clinical indications, announced today that the company has received CE-Mark for its BlueWind RENOVA System, the first in the world miniature wireless neurostimulator to treat Overactive Bladder (OAB).

Vascular Dynamics Appoints James T. McKinley as Chief Operating Officer

Vascular Dynamics, Inc., a privately held medical device company developing novel solutions for the treatment of hypertension, today announced the appointment of James T. McKinley as Chief Operating Officer.

Rainbow Medical to Collaborate With Johnson & Johnson Innovation

Rainbow Medical, a company owned by Leon Recanati, Efi Cohen-Arazi and Yossi Gross, is dedicated to the development of medical device companies. Today they announced a collaboration with Medos International Sarl, part of the DePuy Synthes Companies of Johnson & Johnson. This deal was facilitated by Johnson & Johnson Innovation. The collaboration will be focused on the development of a novel therapy for treating spinal degenerative disc disease.

BlueWind Medical Announces Successful Completion of Patients’ Enrolment for Its Overactive Bladder (OAB) Clinical Study Toward a CE Mark

Bluewind Medical, developer of a wireless neuro-stimulation device to treat multiple clinical indications, such as back pain, peripheral neuropathic pain, incontinence (OAB), epilepsy, and more, announced today the completion of patient enrolment for an Overactive Bladder (OAB) study which is currently being conducted to support CE Mark submission.